Clinical data highlight survival benefits and improvement in functional motor outcomes associated with treatment with doxecitine (dC) and ...

Belgium’s largest drugmaker UCB (Euronext: UCB) today announced positive data from studies involving its investigational ...

UCB, a global biopharmaceutical company, today announced positive data from studies involving its investigational pyrimidine nucleoside therapy, doxecitine (dC) and doxribtimine (dT), in people living ...